Agree this morning is the consolidation on volume that was...

Agree this morning is the consolidation on volume that was required & the CR was a great way to manufacture this.

However, I feel it will only last a couple of hours. IMO this closes today green & very green which will be the beginning of its epic re-rate.

This stock has not really been held by the Insto community (I recall reading this somewhere - maybe * or something). The CR was an opportunity for some Insto's to get set with a teaser position on which they IMO will build.

The announcement today is very telling - ie - New Institutions from USA, Europe, Asia & Australia... The key word here is NEW.

Being conservative & saying it was only 1 New Institution from each region, that's AT LEAST 4 new institutions on the registry.

IMO the US & European Insto's will go crazy for this stock as it is ALREADY GENERATING REVENUE in Australia (for OA) under the special access scheme... There is a stock report in the marketplace out there that says it can do $25m revenue in Aus Alone before even the Phase 3 trials in the US are complete!!

Don't worry about daily or hourly moves on this one - IMO tuck it away & let the insto's rip it in to a valuation in the Billions

Don't forget that the active ingredient in the drug has previously been FDA approved.... the only difference now is that it's being re-purposed...